TheraRadar

Clinical-Stage Biotech Companies

Pre-Approval

Pre-revenue biotechs with active clinical programs — no FDA-approved drugs yet. Data updated: Jun 28, 2026

A clinical-stage company is a biotech with drug candidates in human clinical trials but no FDA-approved product yet — so its value rides almost entirely on its pipeline. This tracker covers every industry sponsor on ClinicalTrials.gov that fits that definition (3,804 companies), ranked by a pipeline-strength score so you can see who is furthest along. Use it to spot acquisition targets, scout competitors in an indication, or surface early-stage names approaching a Phase 3 readout.

Spot Acquisition Targets Before the Bidding War

VCs & Investors: Early-stage bets with Phase 3 catalysts approaching
Pharma M&A: Pipeline acquisitions before approval de-risks the asset
Pipeline Scouting: Who's developing in your indication without an approved drug yet
3,804
Companies tracked
Pre-approval, on ClinicalTrials.gov
1,600
With a Phase 3 program
Near potential approval
2187
Phase 3 trials
Across the top 200 shown
322
Avg pipeline score
Top 200 shown

How We Find These Companies

We analyze ClinicalTrials.gov for INDUSTRY sponsors without FDA-approved drugs. Score = Phase 3 × 15 + Phase 2 × 8 + Phase 1 × 3 + Recent Trials × 5. Higher scores indicate stronger pipeline activity.

Frequently asked questions

What is a clinical-stage company?

A clinical-stage company is a biotech with one or more drug candidates in human clinical trials but no FDA-approved product on the market yet. With no approved-drug revenue, its valuation depends almost entirely on the strength and progress of its pipeline.

How is the pipeline strength score calculated?

Each company is scored by weighting its trials by phase and recency: Phase 3 × 15 + Phase 2 × 8 + Phase 1 × 3 + trials started in the last 12 months × 5. A higher score means a larger, later-stage, more active pipeline.

Where does the data come from?

We analyze ClinicalTrials.gov for industry-sponsored trials run by companies with no FDA-approved drugs, then aggregate each sponsor’s trial counts, phases, therapeutic areas, and HQ country. The data refreshes weekly.

What do the Active, Slowing, Stale, and Inactive labels mean?

They reflect how recently a company started a new trial: Active = a new trial in the last 12 months; Slowing = no new trial in 1–2 years; Stale = none in 2+ years; Inactive = none in 3+ years (the company may have been acquired, wound down, or pivoted).

Clinical-Stage Company Screener

Filter and sort every clinical-stage biotech by phase, activity, geography, and pipeline score — with CSV export.

Limited-time launch pricing
$99/month
30-day free trial - no credit card
Upgrade to Pro

Or explore free dashboards — PDUFA calendar, Trials Explorer, Biotechs, and more.